Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain

Contraception

Volumn 80, Issue 5, 2009, Pages 457-462

  Arribas Mir, Lorenzo ^a,b,e   Rueda Lozano, Dolores ^a,e   Agrela Cardona, María ^a,e   Cedeño Benavides, Tania ^a,e   Olvera Porcel, Carmen ^d   Bueno Cavanillas, Aurora ^b,c,d  

^a University Health Centre of La Chana   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e Andalusian Health Service   (Spain)

Author keywords

Contraception; Etonogestrel; Family physician; Implanon; Primary care; Subdermal implants

Indexed keywords

ETONOGESTREL;

ABDOMINAL PAIN; ACNE; ADOLESCENT; ADULT; ARTICLE; BLEEDING; CONSULTATION; CONTRACEPTIVE DEVICE; CONTROLLED STUDY; DRUG INDUCED HEADACHE; EDEMA; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HIRSUTISM; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MASTALGIA; MEDICAL RECORD REVIEW; MOOD CHANGE; NAUSEA; NULLIPARA; OVARY CYST; SIDE EFFECT; SPAIN; UNSPECIFIED SIDE EFFECT; VAGINAL DRYNESS; WEIGHT GAIN;

ADOLESCENT; ADULT; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG IMPLANTS; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENSTRUATION DISTURBANCES; MIDDLE AGED; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349759575     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.04.003     Document Type: Article

References (31)

1. Voluntary interruption of pregnancy. Andalusía 2002-2003. Evolution of V.I.P. incidence. Years 1991-2003. Spa. Consejería de Salud. Junta de Andalucía. Sevilla 2005. Available at:. http://www.juntadeandalucia.es/salud/principal/documentos.asp?pagina=estadisticas_ive_accede
2. Trussell J. Contraceptive efficacy. In: Hatcher R.A., Trussell J., Nelson A.L., Cates W., Stewart F., and Kowal D. (Eds). Contraceptive Technology: Nineteenth Revised Edition (2007), Ardent Media, New York, NY 747-826
3. Le J., and Tsourounis C. Implanon: a critical review. Ann Pharmacother 35 (2001) 329-336
4. Jordan A. Toxicology of progestogens of implantable contraceptives for women. Contraception 65 (2002) 3-8
5. Edwards J.E., and Moore A. Implanon. A review of clinical studies. Br J Fam Plann 24 4 Suppl (1999) 3-16
6. Mattos I., Martinez C., Ripolles M., et al. Satisfaction, efficacy, side effects of the subdermal implant Implanon® In two advice centers for women of the Community of Madrid. Rev Iberoam Fertil 21 (2004) 93-99 [In Spanish]
7. Davie J.E., Walling M.R., Mansour D.J., Bromham D., Kishen M., and Fowler P. Impact of patient counselling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 18 (1996) 150-159
8. World Health Organization. Reproductive health and research. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. 3rd ed. (2004), WHO, Geneva. http://www.who.int/reproductive-health/ Available at:
9. Belsey E.M., Machin D., and d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34 (1986) 253-260
10. World Health Organization. Selected practice recommendations for contraceptive use. 2nd ed. (2005), WHO, Geneva. http://www.who.int/reproductive-health/ Available at:
11. Otero J.B., Balderas M.L., Bonilla M.C., and Vazquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet 90 (2005) 228-233
12. Rai K., Gupta S., and Cotter S. Experience with Implanon in a northeast London family planning clinic. Eur J Contracept Reprod Health Care 9 (2004) 39-46
13. Agrawal A., and Robinson C. An assessment of the first 3 years' use of Implanon in Luton. J Fam Plann Reprod Health Care 31 (2005) 310-312
14. Lakha F., and Glasier A.F. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception 74 (2006) 287-289
15. Murat M., Yildirim Y., Ertopcu K., Eftal M., Ozelmas I., and Tinar S. Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up). Eur J Contracept Reprod Health Care 13 (2008) 238-242
16. Vieira C.S., Ferriani R.A., García A.A., et al. Use of etonogestrel-releasing implant is associated with hypoactivation of coagulation cascade. Hum Reprod 22 (2007) 2196-2201
17. Belsey E.M., and Farley T.M.M. The analysis of menstrual bleeding patterns: a review. Contraception 38 (1988) 129-156
18. Ginegranada Clinic. (Internet Page). Granada. (Quantitative and comparative study in relation to abortion and other aspects of reproductive health of immigrant women). Spa. Inc.; c2004-2007 (updated 2008 Dec 14; cited 2009 Jan 25). Available at: http://www.ginegranada.com.
19. V Questionnaire Bayer Schering Pharma. Contraception in Spain 2007. (Internet Page). Spa. Daphne Group. (Update 2007; cited 2009 Abril 6). Available at: http://www.equipodaphne.es/encuestas.php.
20. Zheng S.R., Zheng H.M., Qian S.Z., Sang G.W., and Kaper R.F. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 60 (1999) 1-8
21. National Institute for Health and Clinical Excellence. (Internet Page). London. Long-acting reversible contraception. Economic evaluation; p 113-136. Inc.; c2007 (updated 2007 Oct 26; cited 2009 24 Jan). Available at: http://www.nice.org.uk/nicemedia/pdf/CG030fullguideline.pdf.
22. Kiriwat O., Patanayindee A., Koetsawang S., Korver T., and Bennink H.J. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 3 (1998) 85-91
23. Affandi B., Korver T., Geurts T.B., and Coelingh Bennink H.J. A pilot efficacy study with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for ≤4 years. Contraception 59 (1999) 167-174
24. Croxatto H.B., Urbancsek J., Massai R., Coelingh Bennink H., and van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 14 (1999) 976-981
25. Zheng S.R., Zheng H.M., Qian S.Z., Sang G.W., and Kaper R.F. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care 4 (1999) 85-93
26. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 58 6 Suppl (1998) 99S-107S
27. Darney P., Patel A., Rosen K., Shapiro L.S., and Kaunitz A.M. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 18 (2008) 10.1016/j.fertnstert.2008.02.140
28. Aubeny E. Will period-free hormonal contraception become the norm of the twenty-first century?. Eur J Contracept Reprod Health Care 11 (2006) 1-5
29. Harrison-Woolrycha M., and Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 71 (2005) 306-308
30. Webb A.M. Why go to Tiger Country? A report of two cases of Implanon removal. J Fam Plann Reprod Health Care 32 (2006) 193-194
31. Wechselberger G., Wolfram D., Pulzl P., Soelder E., and Schoeller T. Nerve injury caused by removal of an implantable hormonal contraceptive. Am J Obstet Gynecol 195 (2006) 323-326